Despite the availability of genomic testing and new treatments including immunotherapy, cancer outcomes have not changed much over the years. However this may be poised to change. In this panel discussion with representatives from medicine, industry and patient advocacy, we will discuss new molecular testing technologies that are enabling the diagnosis and treatment of solid cancers across all disease stages, impacting patient outcomes and lowering healthcare costs. Dare we hope that cancer may be a chronic disease in the not so distant future?
Ronnie Andrews joined OncoCyte as CEO in July 2019. Prior to this, Ronnie was the founder and principal of the Bethesda Group LLC, a boutique consulting group focused on helping small and mid-stage diagnostic companies move emerging diagnostic content and platforms into the marketplace. Ronnie has close to 30 years of experience in the US Clinical and Molecular Diagnostics industry. He served as the President of the Genetic Science Division for Thermo Fisher Scientific until December 2014. Prior to this Ronnie held a number of other high-profile executive roles including CEO of Clarient, a public company on the NASDAQ which was sold to General Electric Healthcare in 2010.